Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Videos
Interview with the Innovators
December 2016, Vol 7, No 11
Employers Look to Manage the Benefits of Specialty Pharmacy
By
Wayne Kuznar
Employers’ Perspective
,
Specialty Pharmacy
,
Value Peer-spectives
December 2016, Vol 7, No 11
Washington, DC—Employers recognize that oncology care is expensive, and they are shifting their focus on cost management. As such, employers are seeking approaches to determine which drugs and health plan designs will help them manage pharmacy and medical costs to improve patient outcomes, said F. Randy Vogenberg, PhD, RPh, Partner, Access Market Intelligence, and National Institute of Collaborative Healthcare, Greenville, SC, at the Sixth Annual Conference of the Association for Value-Based Cancer Care.
Watch Video
Navigating Patient Assistance Programs
By
Jessica Miller
Patient Navigation
,
Patient Support Services
,
Policies & Guidelines
December 2016, Vol 7, No 11
Washington, DC—In the past 6 years, more than $4 billion in charitable assistance has been dedicated to patients in need. In 2015 alone, the Patient Access Network (PAN) Foundation provided $950 million in cancer care support. The only people with deep enough pockets to support this type of assistance are drug manufacturers, adding to an already complicated regulatory environment for charitable assistance programs, said Daniel J. Klein, President and Chief Executive Officer, PAN Foundation, at the Sixth Annual Conference of the Association for Value-Based Cancer Care.
Watch Video
Cost, Access, and Delivery Challenge New Oncology Drug Options
By
Wayne Kuznar
Economics & Value
,
Value in Oncology
December 2016, Vol 7, No 11
Washington, DC—Although significant advancements in oncology research, development, and treatment have improved cancer care, they have been accompanied by rising drug costs, and differences in drug availability and delivery worldwide. These trends will continue into 2020, according to Douglas Long, Vice President, Industry Relations, IMS Health.
Watch Video
Value-Based Oncology Management and Outcomes-Based Contracting
By
Wayne Kuznar
Economics & Value
,
Value in Oncology
December 2016, Vol 7, No 11
Washington, DC—An innovative, value-based approach to managing the cost of oncology care moves away from drug-spending volume toward the appropriate use and quality of drug therapy, said Alan Lotvin, MD, Executive Vice President, Specialty Pharmacy, CVS Health, Woonsocket, RI, at the Sixth Annual Conference of the Association for Value-Based Cancer Care.
Watch Video
Cost-Savings Measures Will Dot the Oncology Landscape
By
Wayne Kuznar
Value in Oncology
December 2016, Vol 7, No 11
Washington, DC—Risk arrangements with physicians and transferring the costs of care onto patients are expected to increase in 2017, as payers attempt to manage high-cost disease states, such as cancer care, said Marie A. Hollowell, Senior Manager, Syndicated Research, Zitter Health Insights, at the Sixth Annual Conference of the Association for Value-Based Cancer Care.
Watch Video
ASCO CEO Addresses Quest for Value in Cancer Care
By
Wayne Kuznar
Economics & Value
,
Value in Oncology
December 2016, Vol 7, No 11
Washington, DC—Treatments and technologies for cancer care are becoming increasingly expensive, fueling a need to define and improve value. As a result, the American Society of Clinical Oncology (ASCO) is refining its value framework that supports informed shared decision-making between doctors and patients and considers the clinical benefit, cost, and toxicity of cancer treatments. The goal is to have a tool that can customize information for each patient.
Watch Video
Quality Measures Are Key to Supporting Drug Value
By
Wayne Kuznar
Economics & Value
,
Value in Oncology
December 2016, Vol 7, No 11
Washington, DC—An opportunity for value enhancement from the drug manufacturer’s perspective includes the improved use of data to meet the needs of stakeholders, especially the patient. Data that are generated should support the value of the manufacturer’s therapies in light of newly established value-based models, which often rely on quality metrics, for example, that are not obvious from clinical trials. Finally, wraparound services can add to a drug’s value and help to distinguish it from a competitor’s drug.
Watch Video
Cancer Treatment Costs and Trends Beckon Risk-Sharing Future
By
Wayne Kuznar
Economics & Value
,
Value in Oncology
December 2016, Vol 7, No 11
Washington, DC—Oncology care is facing rising costs that will demand a transformation from a fee-for-service reimbursement model to a value-based, shared-risk incentive plan for Medicare and commercial insurance plans. Bruce Pyenson, FSA, MAAA, Principal and Consulting Actuary, Milliman, New York, NY, provided an overview of the cost trends of cancer treatment costs at the Sixth Annual Conference of the Association for Value-Based Cancer Care.
Watch Video
PhRMA’s Perspective on Value-Driven Healthcare
By
Wayne Kuznar
Value in Oncology
December 2016, Vol 7, No 11
Washington, DC—Payers are increasingly evaluating methods to manage oncology care costs in the new value-driven healthcare system. These methods include improved quality measurement and value-assessment tools, the appropriate use of drugs, and value-based contracts with health plans.
Watch Video
FDA News - December 2016
FDA Approvals, News & Updates
December 2016, Vol 7, No 11
Watch Video
The Impact of Policy and Politics on Health and Drug Pricing
By
Jessica Miller
Health Policy
,
Policies & Guidelines
December 2016, Vol 7, No 11
Washington, DC—A panel discussion on health and drug politics took place at the Sixth Annual Conference of the Association for Value-Based Cancer Care. The expert panel included Kavita Patel, MD, Johns Hopkins Medicine, Baltimore; Dan Todd, Principal of Todd Strategy, Washington, DC; and Liz Fowler, Vice President, Global Health Policy, Johnson & Johnson. The panel discussed what is working in healthcare, what is not, and where cancer care fits into it all.
Watch Video
Integrated Care Models Are the Future of Oncology
By
David Knight
Integrated Care Models
December 2016, Vol 7, No 11
Washington, DC—Payer-directed programs, including the integration of oncology into accountable care organizations (ACOs), are likely to become increasingly important for managing the total cost of cancer care, said Michael Kolodziej, MD, National Medical Director, Managed Care Strategy, Flatiron Health, New York, NY, at the Sixth Annual Conference of the Association for Value-Based Cancer Care.
Watch Video
Practice Transformation Essential to the Oncology Care Model
By
Wayne Kuznar
Integrated Care Models
December 2016, Vol 7, No 11
Washington, DC—Transforming an oncology practice into one that incorporates value involves several key elements, including improved collaboration and coordination among the treating physicians and team building, said Diana Verrilli, Vice President and General Manager, Managed Care, Quality and Provider Solutions, McKesson Specialty Health, The Woodlands, TX, at the Sixth Annual Conference of the Association for Value-Based Cancer Care.
Watch Video
Increasing Patient Enrollment in Clinical Trials Key to Progress in Cancer Care
By
Jessica Miller
Clinical Trials
,
Personalized Medicine
December 2016, Vol 7, No 11
Washington, DC—Patient involvement in clinical trials will impact the Cancer Moonshot’s goal of achieving 10 years of progress in 5 years’ time, said Kim Thiboldeaux, Chief Executive Officer, Cancer Support Community, Washington, DC, at the Sixth Annual Conference of the Association for Value-Based Cancer Care.
Watch Video
Genomic Assays Expediting Adoption of Personalized Cancer Therapy in Clinical Practice
By
Wayne Kuznar
Personalized Medicine
December 2016, Vol 7, No 11
Washington, DC—Cancer is now recognized as a disease of the genome. The use of genomic assays and measurement of protein expression are permitting the use of personalized cancer therapy in the clinical setting on a scale not seen previously. In many cases, the use of these assays will also enhance the cost-effectiveness of cancer therapy, although the overall cost of cancer care may not decline as a result, said Gerald Messerschmidt, MD, FACP, Chief Medical Officer, Precision for Medicine, at the Sixth Annual Conference of the Association for ValueBased Cancer Care.
Watch Video
Page 1 of 2
1
2
View the Latest Issue of VBCC
Read Issue
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma